MAPT-Targeting Oligonucleotides for Tau Pathway Gene Silencing
Solution Overview
Problem
Current therapies are inadequate for effectively halting or reversing the progression of neurodegenerative diseases associated with MAPT mutations, such as Alzheimer's and Parkinson's, which involve tau protein regulation.
Innovation Solution
Development of RNA molecules with nucleic acid sequences complementary to MAPT sequences to silence MAPT mRNA expression, including branched oligonucleotides with specific sequences and structures for targeted gene silencing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat neurodegenerative diseases, then treatment is provided, but they are inadequate for effectively halting or reversing disease progression
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism by designing RNA molecules that specifically bind to and silence MAPT mRNA, isolating the disease-causing element (tau protein overexpression) for targeted intervention rather than using broad-spectrum therapies
Solution Approach 2:
The patent changes the therapeutic parameter from general neuroprotection to specific gene silencing by using RNA molecules with specific sequences complementary to MAPT mRNA, altering the mechanism of action to achieve more effective disease modification
2Measurement precision
If RNA molecules are designed to silence MAPT mRNA expression, then tau protein pathways are targeted, but specificity and potency must be optimized
Solution Approach 1:
The patent applies local quality by designing RNA molecules with specific sequence regions that provide different functions: some regions provide binding specificity to MAPT mRNA while other regions provide structural stability, creating localized functional zones within the molecule
Solution Approach 2:
The patent uses composite materials by combining different chemical modifications in the RNA molecule, including modified nucleotides and backbone modifications, to create a composite oligonucleotide structure that achieves both specificity and stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNA molecules effectively reduce MAPT mRNA expression, potentially mitigating the progression of neurodegenerative diseases by targeting tau protein pathways.
Implementation Method 1
an RNA molecule having a nucleic acid sequence that is substantially complementary to a MAPT nucleic acid sequence
Data Source
AI summary
This disclosure relates to novel MAPT targeting sequences. Novel MAPT targeting oligonucleotides for the treatment of neurodegenerative diseases are also provided.